Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients with Ulcerative Colitis: A Randomized Clinical Trial

JAMA - Journal of the American Medical Association

Volumn 321, Issue 2, 2019, Pages 156-164

  Costello, Samuel P ^a,b,c   Hughes, Patrick A ^a   Waters, Oliver ^d   Bryant, Robert V ^a,b,c   Vincent, Andrew D ^a   Blatchford, Paul ^e   Katsikeros, Rosa ^c   Makanyanga, Jesica ^d   Campaniello, Melissa A ^a   Mavrangelos, Chris ^a   Rosewarne, Carly P ^e   Bickley, Chelsea ^e   Peters, Cian ^b   Schoeman, Mark N ^a,b   Conlon, Michael A ^e   Roberts Thomson, Ian C ^a,c   Andrews, Jane M ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

^d FIONA STANLEY HOSPITAL   (Australia)

^e CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID; ENEMA; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE;

ADULT; ANEMIA; AUSTRALIA; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLONOSCOPY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FOLLOW UP; HUMAN; HYPERAMYLASEMIA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT SAFETY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TERTIARY CARE CENTER; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; ALLOTRANSPLANTATION; ANAEROBIC GROWTH; AUTOTRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; INTESTINE FLORA; METABOLOME; MIDDLE AGED; PROCEDURES; QUESTIONNAIRE; YOUNG ADULT;

ADULT; ANAEROBIOSIS; COLITIS, ULCERATIVE; COLONOSCOPY; DOUBLE-BLIND METHOD; ENEMA; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; METABOLOME; MIDDLE AGED; REMISSION INDUCTION; SURVEYS AND QUESTIONNAIRES; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 85059955924     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.20046     Document Type: Conference Paper

References (23)

1. Höie O, Wolters F, Riis L,; European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD). Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007; 102 (8): 1692-1701. doi: 10.1111/j.1572-0241.2007.01265.x 17555460
2. Parragi L, Fournier N, Zeitz J,; Swiss IBD Cohort Study Group. Colectomy rates in ulcerative colitis are low and decreasing: 10-year follow-up data from the Swiss IBD Cohort Study. J Crohns Colitis. 2018; 12 (7): 811-818. doi: 10.1093/ecco-jcc/jjy040 29617750
3. Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014; 39 (7): 645-659. doi: 10.1111/apt.12651 24612141
4. Khan KJ, Ullman TA, Ford AC, Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis [published correction appears in Am J Gastroenterol. 2011;106(5):1014]. Am J Gastroenterol. 2011; 106 (4): 661-673. doi: 10.1038/ajg.2011.72 21407187
5. Sheehan D, Shanahan F. The gut microbiota in inflammatory bowel disease. Gastroenterol Clin North Am. 2017; 46 (1): 143-154. doi: 10.1016/j.gtc.2016.09.011 28164847
6. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017; 389 (10080): 1756-1770. doi: 10.1016/S0140-6736(16)32126-2 27914657
7. van Nood E, Vrieze A, Nieuwdorp M, Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368 (5): 407-415. doi: 10.1056/NEJMoa1205037 23323867
8. Cammarota G, Masucci L, Ianiro G, Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015; 41 (9): 835-843. doi: 10.1111/apt.13144 25728808
9. Costello SP, Chung A, Andrews JM, Fraser RJ. Fecal Microbiota transplant for Clostridium difficile colitis-induced toxic megacolon. Am J Gastroenterol. 2015; 110 (5): 775-777. doi: 10.1038/ajg.2015.70 25942309
10. Li YT, Cai HF, Wang ZH, Xu J, Fang JY. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther. 2016; 43 (4): 445-457. doi: 10.1111/apt.13492 26662643
11. Rossen NG, Fuentes S, van der Spek MJ, Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015; 149 (1): 110-118.e4. doi: 10.1053/j.gastro.2015.03.045 25836986
12. Moayyedi P, Surette MG, Kim PT, Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015; 149 (1): 102-109.e6. doi: 10.1053/j.gastro.2015.04.001 25857665
13. Paramsothy S, Kamm MA, Kaakoush NO, Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017; 389 (10075): 1218-1228. doi: 10.1016/S0140-6736(17)30182-4 28214091
14. Chu ND, Smith MB, Perrotta AR, Kassam Z, Alm EJ. Profiling living bacteria informs preparation of fecal microbiota transplantations. PLoS One. 2017; 12 (1): e0170922. doi: 10.1371/journal.pone.0170922 28125667
15. Rutgeerts P, Sandborn WJ, Feagan BG, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353 (23): 2462-2476. doi: 10.1056/NEJMoa050516 16339095
16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955; 2 (4947): 1041-1048. doi: 10.1136/bmj.2.4947.1041 13260656
17. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998; 43 (1): 29-32. doi: 10.1136/gut.43.1.29 9771402
18. Costello SP, Tucker EC, La Brooy J, Schoeman MN, Andrews JM. Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis. 2016; 62 (7): 908-914. doi: 10.1093/cid/civ994 26628567
19. Campaniello MA, Mavrangelos C, Eade S, Acute colitis chronically alters immune infiltration mechanisms and sensory neuro-immune interactions. Brain Behav Immun. 2017; 60: 319-332. doi: 10.1016/j.bbi.2016.11.015 27864046
20. Mavrangelos C, Campaniello MA, Andrews JM, Bampton PA, Hughes PA. Longitudinal analysis indicates symptom severity influences immune profile in irritable bowel syndrome. Gut. 2018; 67 (2): 398-399. doi: 10.1136/gutjnl-2017-314308 28601848
21. Brinkworth GD, Noakes M, Clifton PM, Bird AR. Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populations. Br J Nutr. 2009; 101 (10): 1493-1502. doi: 10.1017/S0007114508094658 19224658
22. Borody T, Wettstein A, Campbell J, Fecal microbiota transplantation in ulcerative colitis: review of 24 years experience. Am J Gastroenterology. 2012; 107: S665.
23. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 2015; 42 (8): 1011-1018. doi: 10.1111/apt.13366 26264455